#ViiV Healthcare

ViiV Healthcare has reported promising one-year findings from a study of a two-drug injectable treatment given every four weeks.

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

Researchers presented 100-week data on a trial of the antiretroviral (ARV) regimen at the international AIDS conference.

Full 48-week results comparing Tivicay plus Epivir with Tivicay plus Truvada were presented at the International AIDS Conference.

“As Much As I Can” debuted in the South. This week, it opens in Harlem, New York.

Forty-eight-week results are in from a Phase III study that switched participants from Triumeq to Gilead’s new single-tablet regimen.

ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).

Who are the top 20 funders across the globe? This annual FCAA report lists them all.

The Southern HIV Impact Fund is a collaborative partnership managed by AIDS United.

The single-tablet regimen contains ViiV’s Tivicay (dolutegravir) and Janssen’s Edurant (rilpivirine).

Early results from an ongoing trial show that 24 weeks after adding the drug to their HIV regimen, half were virally suppressed.

Respondents reported on their feelings about antiretrovirals, their relationships with their clinicians and dealing with stigma.

Called #PWNCares, the multimedia series launches Monday, October 23, from Positive Women’s Network–USA.

AIDS United, NMAC and other HIV leaders can help you help those in dire need. Here’s how.

ViiV Healthcare has applied to the FDA for approval of the first two-drug antiretroviral (ARV) regimen to treat HIV.